No information available.
The investment objective is to secure capital growth from a portfolio of securities of companies engaged in Health and Pharmaceuticals. Securities representing all such companies in the developed and advanced emerging segments of the FTSE All-World Index will normally be held with weighting generally proportionate to their market capitalisation.
The largest 90% of companies by market cap are covered, which number around 90. Since Pfizer exceeds the 10% limit in any one stock imposed by IMRO, the trust will hold Medium Term Notes to simulate the performance of the shares. The fund fully replicates the index.